Trial Profile

A Phase III Randomized, Double-blinded Trial of Platinum-based Chemotherapy With or Without Atezolizumab Followed by Niraparib Maintenance With or Without Atezolizumab in Patients With Recurrent Ovarian, Tubal or Peritoneal Cancer and Platinum Treatment-free Interval (TFIp) >6 Months

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 30 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Carboplatin (Primary) ; Doxorubicin liposomal (Primary) ; Gemcitabine (Primary) ; Niraparib (Primary) ; Paclitaxel (Primary)
Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Therapeutic Use
Acronyms ANITA

30 Aug 2024 Status changed from active, no longer recruiting to completed.
11 Jul 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.
24 Oct 2023 Primary analysis results ( at the data cut-off 15 Apr 2023, n=417) presented at the 48th European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com